RecruitingNot ApplicableNCT05116384

Renal Denervation + PVI vs PVI Alone for Persistent AF

A Trial to Evaluate Renal Artery Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation

Sponsor

University of Rochester

Enrollment

50 participants

Start Date

Jul 30, 2023

Study Type

INTERVENTIONAL

Conditions

Atrial Fibrillation

Summary

Pulmonary vein isolation (PVI) is the cornerstone of ablation for atrial fibrillation (AF). Increased cardiac sympathetic stimulation can facilitate AF and reduction can be accomplished by renal artery denervation (RDN). The recently completed randomized trial, ERADICATE-AF, convincingly demonstrated that RDN plus PVI resulted in a reduction in recurrent incident AF for uncontrolled hypertensives. This is a randomized controlled pilot trial, "To Evaluate Renal Artery Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation" (ERADICATE-AF II) to test if RDN plus PVI enhances long-term efficacy vs PVI for persistent AF patients with controlled or without hypertension using implantable loop recordings.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Age \> 18 years
Symptomatic persistent AF eligible for referral for PVI based on current guidelines1 (persistent AF defined as continuation \> 7 days and up to 1 year)
No prior history of HTN or HTN controlled on medical therapy (defined as SBP \<140 mm Hg and DBP \<85 mm Hg)
Renal vasculature accessible as determined by pre-procedural renal magnetic resonance angiogram
Willingness to undergo ILR placement
Willingness to comply with post-procedural follow-up requirements and to sign informed consent.

Exclusion Criteria14

Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus, contraindication to all anticoagulation)
Prior left atrial ablation for an atrial arrhythmia
NYHA class IV congestive heart failure or LVEF \< 25%
Paroxysmal AF, or longstanding persistent AF (duration \> 1 year)
Coronary revascularization or valve surgery within 3 months
Prior valve surgery using a mechanical prosthesis
Renal artery anatomy that is ineligible for treatment including:
Predicted inability to access renal vasculature
Main renal arteries \< 4 mm in diameter or \< 20 mm in length.
Hemodynamically or anatomically significant renal artery abnormality or stenosis
A history of prior renal artery intervention including balloon angioplasty or stenting that precludes a possibility of ablation treatment
Multiple main renal arteries to either kidney
An estimated glomerular filtration rate (eGFR) \< 45mL/min/1.73m2, using the MDRD calculation
Life expectancy \<1 year for any medical condition